Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people lose very little weight in their first week on Mounjaro — and that is entirely normal. The starting dose is 2.5mg, chosen to let your body adjust rather than to drive weight loss, so the scale may barely move at first. Across the full SURMOUNT-1 trial programme, average losses of around 20–21% of body weight took 72 weeks to accumulate, not seven days. Mounjaro (tirzepatide) is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically suitable for you before any treatment begins. If you are weighing up the cost of that process, it helps to understand what a legitimate private prescription actually includes — and why the first week's number is the least useful one to focus on.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first pen you receive contains the 2.5mg starter dose. Its job is not weight loss. Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) which slow how quickly food moves through your stomach and signal fullness to your brain. At 2.5mg, those effects are deliberately mild while your digestive system finds its footing. Nausea, a feeling of fullness after smaller meals, and some fatigue are common in week one; the NHS medicines page for tirzepatide notes these tend to settle within days to a couple of weeks as your body adapts.
In terms of the scale, you might see a small drop from reduced food intake, some water-weight shift, or nothing at all. All three are normal. The first-week weight loss picture varies widely between people, starting weight, water retention, and how much nausea you experience all play a part. Setting expectations here matters, because people who expect rapid early results sometimes question whether the medicine is working. It is; the titration schedule simply has a longer arc than a week.
One thing our prescribers hear regularly: "I paid for this pen and nothing's happened yet." The feeling is understandable. But what's happening at 2.5mg is adjustment, not stagnation. If you're curious about how much weight loss to expect each week on Mounjaro, the picture becomes clearer as doses increase and your body settles into the treatment. The clinical trajectory over the first month starts to tell a more meaningful story.
Private tirzepatide treatment in the UK is priced per pen, per month. Reported market prices since Eli Lilly adjusted its UK list price in September 2025 typically range from around £149 to around £375 a month, depending on dose and provider. Those figures are widely available and hedged here as approximations, individual providers set their own prices.
The more important question is what a headline price actually includes. Some providers quote a per-pen figure that excludes a separate consultation fee, a prescription charge, delivery, and any ongoing dose-review support. Those costs add up quickly. If you are comparing providers on price, the full Mounjaro cost picture (including what sits below the advertised number) is worth understanding before you commit.
At nume, one price covers the clinical consultation, prescription, treatment, free next-working-day DPD delivery, and aftercare. We are not the cheapest option on the market, and that is a deliberate choice: clinical review before every dispatch, a GPhC-registered pharmacy you can verify at GPhC registration number 9012878, and no subscription auto-renewals. Every repeat order is re-reviewed clinically. No surprises on the invoice.
For most purchases, the lowest price is a reasonable starting point. For a prescription-only medicine like Mounjaro, it is the wrong question entirely. The MHRA has warned publicly about counterfeit weight-loss pens sold online, including fake tirzepatide pens seized from an illicit manufacturing site in 2025. Pens sold without a proper prescription and clinical assessment (at prices that look suspiciously low) carry real risks: unknown contents, no cold-chain integrity, no prescriber oversight if something goes wrong.
The right question is whether the provider can be verified on the GPhC pharmacy register, whether a named prescriber reviews your case, and whether genuine supply-chain assurance is built into the price. NICE's appraisal of tirzepatide, TA1026, sets the clinical eligibility criteria this medicine was developed within, adult BMI 35 or above with a qualifying condition, or 30 and above under the licensed private criteria. Meeting those criteria with a real prescriber, not a checkbox form, is what a legitimate cost should reflect.
For a fuller look at what drives long-term results (not just week one) see our overview of expected weight loss on Mounjaro across the full treatment course. And if you want to understand what a specific early dose delivers on average, the 5mg outcomes page covers that in detail.
If you are ready to see whether treatment is clinically appropriate for you, our consultation is free, reviewed the same day, and there is no obligation to proceed. You can also read more about how our clinical team works on the prescriber profile page or explore the full range of weight-loss treatments we offer.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.